Elite Journal of HIV. Volume 1 Issue 1(2023), Pp. 1-14
https://epjournals.com/journals/EJHIV

Management of Aplastic Anemia in HIV-Infected Pediatric Population: Challenges and Opportunities

*Emmanuel Ifeanyi Obeagu[1]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) represents a complex hematologic disorder characterized by bone marrow failure and peripheral blood pancytopenia. In the pediatric population coinfected with human immunodeficiency virus (HIV), the management of AA poses unique challenges, necessitating a nuanced understanding of disease pathogenesis and tailored treatment strategies. This review provides a comprehensive overview of the management of AA in HIV-infected pediatric patients, focusing on diagnostic challenges, treatment options, and emerging therapeutic modalities. Diagnostic evaluation of AA in HIV-infected pediatric patients requires careful consideration of overlapping clinical and laboratory findings, highlighting the importance of a multidisciplinary approach. Current treatment strategies encompass immunosuppressive therapies, hematopoietic stem cell transplantation (HSCT), and supportive care measures, with a growing emphasis on emerging immunomodulatory agents targeting immune dysregulation. Furthermore, effective management of HIV infection with antiretroviral therapy (ART) is essential in optimizing treatment outcomes and preventing HIV-related complications. Despite the challenges, advancements in treatment modalities offer hope for improved outcomes in this vulnerable population.

Keywords: *Aplastic Anemia, HIV, Pediatrics, Management, Treatment Strategies, Immunomodulatory Therapies, Hematopoietic Stem Cell Transplantation, Antiretroviral Therapy*

Introduction

Aplastic anemia (AA) presents a multifaceted hematologic challenge in pediatric patients, particularly when complicated by human immunodeficiency virus (HIV) coinfection. This rare but

Citation: Obeagu EI. Management of Aplastic Anemia in HIV-Infected Pediatric Population: Challenges and Opportunities. Elite Journal of HIV, 2023; 1(1): 1-14

severe disorder is characterized by bone marrow failure, leading to peripheral blood pancytopenia and significant morbidity. In the pediatric population, AA often manifests with nonspecific symptoms such as fatigue, pallor, and increased susceptibility to infections, posing diagnostic challenges that are further compounded in the presence of HIV infection. Understanding the complexities of managing AA in HIV-infected pediatric patients is essential for optimizing treatment outcomes and improving the quality of life in this vulnerable population. Pediatric patients with HIV and AA require a comprehensive diagnostic approach that considers the overlapping clinical and laboratory features of both conditions. Distinguishing between AA-related cytopenias and those attributed to HIV infection necessitates careful evaluation, including a complete blood count, bone marrow examination, and assessment of HIV disease status. The impact of HIV infection on bone marrow function and immune regulation further complicates the diagnostic process, underscoring the importance of a multidisciplinary approach involving hematologists, infectious disease specialists, and pediatricians.[1-10]

Once diagnosed, the management of AA in HIV-infected pediatric patients revolves around a tailored treatment approach aimed at achieving hematopoietic recovery while minimizing the risk of HIV-related complications. Traditional treatment strategies for AA, such as immunosuppressive therapies with anti-thymocyte globulin (ATG) and cyclosporine, remain cornerstone interventions, but their efficacy and safety in the context of HIV coinfection warrant careful consideration. Additionally, hematopoietic stem cell transplantation (HSCT) offers a curative option for eligible patients, although challenges in donor selection, conditioning regimens, and post-transplant care persist. Emerging immunomodulatory therapies present promising avenues for the management of AA in HIV-infected pediatric patients, offering alternatives to traditional immunosuppressive regimens. These novel agents, including anti-cytokine therapies and immune checkpoint inhibitors, aim to target dysregulated immune responses while preserving immune function and promoting hematopoietic recovery. Furthermore, the role of antiretroviral therapy (ART) in optimizing treatment outcomes and preventing HIV-related complications cannot be overstated, highlighting the importance of comprehensive HIV management in this population. Despite the challenges inherent in managing AA in HIV-infected pediatric patients, advancements in treatment modalities offer hope for improved outcomes and enhanced quality of life. Collaborative efforts between healthcare providers, researchers, and pharmaceutical stakeholders are essential for advancing the field and addressing the unmet needs of this vulnerable population. By elucidating the complexities of AA management in the context of HIV infection, this review aims to provide insights into optimal treatment strategies and pave the way for improved clinical outcomes in affected individuals.[11-20]

Epidemiology and Clinical Presentation

Epidemiology

The epidemiology of aplastic anemia (AA) in the pediatric population coinfected with human immunodeficiency virus (HIV) remains poorly defined due to its rarity and the challenges associated with diagnosis and reporting. While AA is considered a rare disorder overall, its

prevalence may be higher in HIV-infected pediatric patients compared to the general population due to the immunosuppressive effects of HIV and potential exposure to myelosuppressive antiretroviral therapies (ART). However, accurate epidemiological data on the incidence and prevalence of AA in HIV-infected pediatric patients are limited, highlighting the need for further research in this area.[21-23]

Clinical Presentation

The clinical presentation of AA in HIV-infected pediatric patients may vary widely, ranging from asymptomatic cytopenias to severe bone marrow failure requiring urgent intervention. Children with AA and HIV often present with nonspecific symptoms such as fatigue, pallor, and increased susceptibility to infections. Mucosal bleeding, petechiae, and ecchymoses may also occur due to thrombocytopenia. In severe cases, life-threatening complications such as hemorrhage and severe infections may develop, necessitating prompt diagnosis and intervention. The clinical presentation of AA in HIV-infected pediatric patients may be further complicated by concurrent manifestations of HIV infection, including opportunistic infections, lymphadenopathy, hepatosplenomegaly, and failure to thrive. Distinguishing between AA-related cytopenias and those attributed to HIV-related complications can be challenging, requiring a thorough evaluation of clinical and laboratory findings. Diagnostic workup typically includes a complete blood count, peripheral blood smear, bone marrow examination, and assessment of HIV disease status. Given the potential overlap in clinical features between AA and HIV-related cytopenias, a high index of suspicion is crucial in identifying AA in HIV-infected pediatric patients. Diagnostic confirmation often requires bone marrow examination to assess cellularity, morphology, and the presence of dysplastic changes or marrow suppression. Ancillary tests, including flow cytometry, cytogenetic analysis, and assessment of telomere length, may also be performed to further characterize the underlying etiology of cytopenias.[24-30]

Diagnostic Challenges

Diagnosing aplastic anemia (AA) in pediatric patients coinfected with human immunodeficiency virus (HIV) poses several challenges due to overlapping clinical and laboratory features, as well as the complexity of managing two distinct hematologic disorders concurrently. The clinical presentation of AA and HIV-related cytopenias can be similar, with both conditions manifesting as fatigue, pallor, and increased susceptibility to infections. Distinguishing between AA-related cytopenias and those attributed to HIV infection or its associated complications requires careful evaluation and a high index of suspicion. Interpretation of hematologic parameters, such as peripheral blood counts and bone marrow findings, can be challenging in the context of HIV infection. HIV-related cytopenias, opportunistic infections, and drug-related toxicities may contribute to abnormalities in blood cell counts and morphology, making it difficult to differentiate between primary and secondary causes of cytopenias. Definitive diagnosis of AA often requires bone marrow examination to assess cellularity, morphology, and the presence of dysplastic changes or marrow suppression. However, bone marrow findings in HIV-infected pediatric patients may be confounded by concurrent manifestations of HIV infection, including

opportunistic infections, infiltration by neoplastic cells, and HIV-associated lymphoproliferative disorders.[31-35]

Assessing HIV disease status, including viral load, CD4+ T-cell count, and immune function, is essential for understanding the impact of HIV infection on hematopoiesis and immune regulation. However, interpreting these parameters in the context of AA can be challenging, as the effects of AA and its treatment modalities may influence HIV disease progression and treatment response. The differential diagnosis of cytopenias in HIV-infected pediatric patients is broad and includes not only AA but also other hematologic disorders, infectious etiologies, drug-related toxicities, and malignancies. Distinguishing between these various etiologies requires a comprehensive diagnostic workup, including laboratory tests, imaging studies, and consultation with specialists as needed. Early recognition and diagnosis of AA in HIV-infected pediatric patients are essential for timely initiation of appropriate treatment and optimization of clinical outcomes. However, delayed diagnosis due to the complexity of clinical presentation and overlapping features with HIV-related complications may result in a missed opportunity for effective intervention.[36-40]

Treatment Strategies

The management of aplastic anemia (AA) in pediatric patients coinfected with human immunodeficiency virus (HIV) requires a multifaceted approach that addresses both the underlying bone marrow failure and the complexities of managing HIV infection. Immunosuppressive therapies, such as anti-thymocyte globulin (ATG) and cyclosporine, remain the mainstay of treatment for AA in pediatric patients, including those with HIV coinfection. These therapies aim to suppress aberrant immune responses targeting hematopoietic stem cells and promote hematopoietic recovery. However, careful monitoring for infectious complications and drug interactions with antiretroviral therapy (ART) is essential. Supportive care measures, including blood transfusions, hematopoietic growth factors (e.g., erythropoietin, granulocyte colony-stimulating factor), and antimicrobial prophylaxis, are essential for managing cytopenias and preventing complications such as infections and bleeding. Close monitoring for signs of infection, mucosal bleeding, and other hematologic complications is warranted, particularly in the setting of HIV coinfection. Hematopoietic stem cell transplantation (HSCT) offers a curative option for eligible pediatric patients with AA, including those with HIV coinfection. However, HSCT in the context of HIV infection poses unique challenges related to donor selection, conditioning regimens, and post-transplant care. Careful consideration of HIV disease status, viral load, and immune function is essential in determining eligibility and optimizing transplant outcomes.[41-45]

Effective management of HIV infection with ART is crucial in HIV-infected pediatric patients with AA. Suppression of HIV viral replication not only reduces the risk of opportunistic infections but also contributes to immune reconstitution and may enhance the efficacy of AA treatment modalities, including immunosuppressive therapies and HSCT. Adherence to ART and close monitoring of HIV disease status are paramount in optimizing treatment outcomes. Emerging immunomodulatory agents, including anti-cytokine therapies and immune checkpoint inhibitors, hold promise in the management of AA in HIV-infected pediatric patients. These novel therapies

aim to target dysregulated immune responses while preserving immune function and promoting hematopoietic recovery. Clinical trials evaluating the efficacy and safety of these agents in pediatric patients with AA and HIV coinfection are warranted. Multidisciplinary care involving hematologists, infectious disease specialists, pediatricians, and other healthcare providers is essential for optimizing treatment outcomes and addressing the unique needs of pediatric patients with AA and HIV coinfection. Close collaboration between specialties, as well as communication with patients and their families, is key to ensuring comprehensive and holistic care.[46-50]

Emerging Therapeutic Modalities

In the management of aplastic anemia (AA) in pediatric patients coinfected with human immunodeficiency virus (HIV), emerging therapeutic modalities offer promising alternatives to traditional treatment approaches. These novel strategies aim to target immune dysregulation, promote hematopoietic recovery, and improve clinical outcomes. Anti-cytokine therapies target dysregulated cytokine signaling pathways implicated in the pathogenesis of AA and HIV-related immune dysregulation. Agents such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) inhibitors aim to modulate immune responses and ameliorate marrow destruction. Clinical trials evaluating the efficacy and safety of anti-cytokine therapies in pediatric patients with AA and HIV coinfection are underway. Immune checkpoint inhibitors, such as antibodies targeting programmed cell death protein 1 (PD-1) and its ligands (PD-L1/PD-L2), have emerged as promising immunomodulatory agents in the treatment of various hematologic disorders. In the context of AA and HIV coinfection, immune checkpoint inhibitors aim to unleash anti-tumor immunity and promote hematopoietic recovery by blocking inhibitory signals that dampen T cell function. Clinical trials investigating the use of immune checkpoint inhibitors in pediatric patients with AA and HIV coinfection are ongoing.[51-55]

Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance and preventing autoimmunity. Dysregulation of Treg function has been implicated in the pathogenesis of AA and HIV-related immune dysregulation. Treg therapy, involving the adoptive transfer of ex vivo expanded Tregs or the induction of endogenous Treg expansion, offers a promising approach to restoring immune balance and suppressing aberrant immune responses in affected individuals. Clinical trials evaluating the efficacy and safety of Treg therapy in pediatric patients with AA and HIV coinfection are underway. Advances in our understanding of the molecular pathways involved in AA and HIV pathogenesis have paved the way for targeted immunomodulatory approaches. These include therapies aimed at modulating specific immune cell subsets, signaling pathways, or cytokine networks implicated in disease pathogenesis. By selectively targeting key mediators of immune dysregulation, targeted immunomodulation offers the potential for more precise and efficacious treatment of AA in pediatric patients with HIV coinfection. Combination therapies involving multiple immunomodulatory agents, as well as their integration with traditional treatment modalities such as immunosuppressive therapies and hematopoietic stem cell transplantation (HSCT), represent a promising approach to enhancing treatment efficacy and improving clinical outcomes in pediatric patients with AA and HIV coinfection. Clinical trials exploring the synergistic effects of combination therapies in this population are underway.[55-60]

Role of Antiretroviral Therapy (ART)

Antiretroviral therapy (ART) plays a pivotal role in the management of aplastic anemia (AA) in pediatric patients coinfected with human immunodeficiency virus (HIV). ART not only suppresses viral replication and reduces the risk of opportunistic infections but also contributes to immune reconstitution and may enhance the efficacy of AA treatment modalities. Effective suppression of HIV viral replication is paramount in pediatric patients with AA and HIV coinfection. ART regimens, consisting of combinations of antiretroviral drugs targeting different stages of the HIV replication cycle, aim to achieve sustained virological suppression and prevent the progression of HIV-related complications. By reducing the HIV viral load, ART mitigates the immunosuppressive effects of HIV and promotes immune reconstitution, thereby creating a more favorable environment for hematopoietic recovery in patients with AA. One of the primary goals of ART in pediatric patients with AA and HIV coinfection is the prevention of opportunistic infections. By restoring immune function and increasing CD4+ T-cell counts, ART reduces the risk of opportunistic infections such as Pneumocystis jirovecii pneumonia, cytomegalovirus infection, and Mycobacterium avium complex disease. Timely initiation and adherence to ART are essential for maximizing its preventive efficacy and reducing the incidence of infectious complications in this vulnerable population.[61-65]

ART-mediated suppression of HIV viral replication leads to immune reconstitution, characterized by increases in CD4+ T-cell counts and restoration of immune function. Immune reconstitution is particularly relevant in the context of AA, where immune dysregulation plays a central role in disease pathogenesis. By enhancing immune surveillance and restoring immune homeostasis, ART may augment the efficacy of AA treatment modalities, including immunosuppressive therapies and hematopoietic stem cell transplantation (HSCT). ART optimization is essential for maximizing treatment outcomes in pediatric patients with AA and HIV coinfection. Close monitoring of HIV viral load, CD4+ T-cell counts, and ART adherence is crucial for assessing treatment response and adjusting ART regimens as needed. Additionally, interdisciplinary collaboration between hematologists, infectious disease specialists, and pediatricians is essential for integrating ART into comprehensive treatment plans and addressing the unique needs of this patient population. Beyond its direct effects on HIV viral replication and immune function, ART plays a critical role in preventing HIV-related complications such as HIV-associated nephropathy, cardiomyopathy, and neurocognitive disorders. By maintaining viral suppression and preserving immune function, ART reduces the risk of HIV-related end-organ damage and improves overall clinical outcomes in pediatric patients with AA and HIV coinfection.[66-75]

Conclusion

The management of aplastic anemia (AA) in the pediatric population coinfected with human immunodeficiency virus (HIV) presents a complex clinical challenge that requires a multidisciplinary and comprehensive approach. Throughout this review, we have explored the epidemiology, diagnostic challenges, treatment strategies, and emerging therapeutic modalities for AA in HIV-infected pediatric patients, highlighting the unique complexities and opportunities in

this population. Despite the rarity of AA in pediatric patients with HIV coinfection, accurate diagnosis and timely intervention are essential for optimizing treatment outcomes and improving the quality of life in affected individuals. Diagnostic challenges, including overlapping clinical and laboratory features, necessitate a high index of suspicion and thorough evaluation to distinguish between primary and secondary causes of cytopenias.

Treatment strategies for AA in HIV-infected pediatric patients encompass a range of modalities, including immunosuppressive therapies, hematopoietic stem cell transplantation (HSCT), supportive care measures, and emerging immunomodulatory agents. Additionally, the role of antiretroviral therapy (ART) in suppressing HIV viral replication, preventing opportunistic infections, promoting immune reconstitution, and optimizing treatment outcomes cannot be overstated. Emerging therapeutic modalities, such as anti-cytokine therapies, immune checkpoint inhibitors, regulatory T cell (Treg) therapy, targeted immunomodulation, and combination therapies, offer promising alternatives to traditional treatment approaches and hold the potential to revolutionize the management of AA in HIV-infected pediatric patients.

References

1. Sankar V, Villa A. Hematologic diseases. Burket's Oral Medicine. 2021:627-664.
2. Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. American journal of clinical pathology. 2013;139(1):9-29.
3. Smith JN, Kanwar VS, MacNamara KC. Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Frontiers in Immunology. 2016; 7:217479.
4. Storb RF, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. ASH Education Program Book. 2003;2003(1):372-397.
5. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. ASH Education Program Book. ;2003(1):294-313.
6. Blood GA. Human immunodeficiency virus (HIV). Transfusion Medicine and Hemotherapy. 2016;43(3):203.
7. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, Alexander H, Hurlston Cox M, Nkengasong JN. Diagnosis of human immunodeficiency virus infection. Clinical microbiology reviews. 2018;32(1):10-128.
8. Opie J. Haematological complications of HIV infection: forum-review. South African Medical Journal. 2012;102(6):465-468.
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023

;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.

11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Gandhi S, Abuarqoub H, Kordasti S, Jiang J, Kulasekararaj A, Mufti G, Marsh JC. Pathology of bone marrow failure syndromes. Diagnostic Histopathology. 2015;21(5):174-180.
20. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
21. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009

Citation: Obeagu EI. Management of Aplastic Anemia in HIV-Infected Pediatric Population: Challenges and Opportunities. Elite Journal of HIV, 2023; 1(1): 1-14

22. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
23. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
24. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
25. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
26. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
27. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
28. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
29. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
30. Bonadies N, Rovó A, Porret N, Bacher U. When should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? A practical approach to diagnosis. Journal of clinical medicine. 2021;10(5):1026.
31. Groarke EM, Young NS, Calvo KR. Distinguishing constitutional from acquired bone marrow failure in the hematology clinic. Best Practice & Research Clinical Haematology. 2021;34(2):101275.

Citation: Obeagu EI. Management of Aplastic Anemia in HIV-Infected Pediatric Population: Challenges and Opportunities. Elite Journal of HIV, 2023; 1(1): 1-14

32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
33. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-

Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.

41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
44. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
45. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
46. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
47. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
48. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
49. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
50. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
51. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
52. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
53. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
54. Wilson CS, Brynes RK. Evaluation of anemia, leukopenia, and thrombocytopenia. Hematopathology E-Book. 2010:154.
55. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Advances. 2021;5(12):2660-2671.
56. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
57. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
58. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
59. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
60. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
61. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
62. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.

Citation: Obeagu EI. Management of Aplastic Anemia in HIV-Infected Pediatric Population: Challenges and Opportunities. Elite Journal of HIV, 2023; 1(1): 1-14

63. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
64. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
65. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
66. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
67. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
68. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
69. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
70. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
71. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
72. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
73. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology. 2022;140(12):1345-1377.
74. Acevedo A, Alférez S, Merino A, Puigví L, Rodellar J. Automatic recognition system of nucleated peripheral blood cell images. Int. J. Lab. Hematol. 2016; 38:1-.
75. Yusuf AA, Musa BM, Galadanci NA, Babashani M, Mohammed AZ, Ingles DJ, Fogo AB, Wester CW, Aliyu MH. HIV-associated nephropathy: Protocol and rationale for an

exploratory genotype-phenotype study in a sub-Saharan African population. Plos one. 2021;16(4):e0249567.